NICE Recommends AUCATZYL CAR-T Therapy for Adult Relapsed/Refractory B-Cell ALL in England and Wales
核心洞察
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending AUCATZYL (obecabtagene autoleucel) for use in the NHS as a treatment option for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (搜索).
AUCATZYL will be available through routine commissioning by the NHS, with Autolus Therapeutics planning an imminent launch in England and Wales following MHRA conditional marketing authorization in April 2025.
The recommendation is based on results from the FELIX study, an open-label, multi-center, single-arm study published in the New England Journal of Medicine in November 2024.
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending AUCATZYL® (obecabtagene autoleucel) for use in the National Health Service (NHS) in England and Wales as a treatment option for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (搜索) (r/r B-ALL). The therapy will be available through routine commissioning by the NHS, with Autolus Therapeutics planning an imminent launch in these regions.
Regulatory Foundation and Clinical Evidence
The NICE recommendation follows the UK Medicines and Healthcare products Regulatory Agency (MHRA) granting conditional marketing authorization for AUCATZYL in April 2025. The regulatory approval was based on results from the FELIX study, an open-label, multi-center, single-arm study in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, with results published in the New England Journal of Medicine in November 2024.
AUCATZYL was previously approved by the FDA for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (搜索) in November 2024, and was granted conditional marketing authorization by the European Medicines Agency (EMA) in the EU in 2025.
Therapy Design and Mechanism
Obecabtagene autoleucel is an autologous CD19 (搜索) chimeric antigen receptor (CAR) T cell therapy featuring a proprietary CD19 CAR design. The therapy was invented by a team led by Dr. Martin Pule at University College London, in collaboration with Great Ormond Street Hospital and University College London Hospitals. AUCATZYL is engineered with a fast target binding off-rate designed to minimize excessive activation of the programmed T cells, potentially overcoming limitations in clinical activity and safety compared to current CD19 CAR T cell therapies.
Industry and Patient Advocacy Response
Dr. Christian Itin, Autolus Chief Executive Officer, stated: "We believe AUCATZYL represents an important new treatment option for eligible adult r/r B-ALL patients. NHS clinical centres and UK patients participated in the development of AUCATZYL and we are looking forward to supporting patients and physicians in England and Wales now with the commercial product."
Patient advocacy organizations have welcomed the NICE recommendation. Henny Braund, Chief Executive of Anthony Nolan (搜索), commented: "B-cell ALL (搜索) is an aggressive disease with a poor prognosis, and there remains a need for additional treatment options. Today's announcement marks an important step towards enabling more patients in England and Wales to access this CAR T therapy."
Fiona Hazell, CEO of Leukaemia UK (搜索), emphasized the collaborative nature of the approval process: "This decision reflects the value of collaboration between Leukaemia UK, Anthony Nolan (搜索) and Leukaemia Care to ensure patient voices were included in the NICE evaluation process. We're especially proud of our patient representative, whose compelling testimony was a vital part of the process."
Market Access Strategy
Autolus Therapeutics intends to pursue patient access to AUCATZYL through the Scottish Medical Consortium in addition to the NHS coverage in England and Wales. The company, described as an early commercial-stage biopharmaceutical company, is developing next-generation programmed T cell therapies using proprietary and modular T cell programming technologies designed to recognize target cells, break down their defense mechanisms and eliminate these cells.
The conditional marketing authorization status means that further evidence on this medicinal product is awaited, reflecting the ongoing development and monitoring requirements for this advanced therapy.